This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for July 11th
by Zacks Equity Research
APNHY, AHCHY, and AMK have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2022.
New Strong Sell Stocks for March 22nd
by Zacks Equity Research
APNHY,BRY, and CSIQ have been added to the Zacks Rank #5 (Strong Sell) List on March 22, 2022.
New Strong Sell Stocks for February 28th
by Zacks Equity Research
PRG, AGESY, and APNHY have been added to the Zacks Rank #5 (Strong Sell) List on February 28, 2022
Recent Price Trend in Aspen Pharmacare (APNHY) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Aspen Pharmacare (APNHY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
ASPEN PHARMACR (APNHY) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
ASPEN PHARMACR (APNHY) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Here's Why "Trend" Investors Would Love Betting on ASPEN PHARMACR (APNHY)
by Zacks Equity Research
ASPEN PHARMACR (APNHY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What Makes ASPEN PHARMACR (APNHY) a Good Fit for "Trend Investing"
by Zacks Equity Research
ASPEN PHARMACR (APNHY) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
ASPEN PHARMACR (APNHY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
ASPEN PHARMACR (APNHY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ASPEN PHARMACR (APNHY) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Has ASPEN PHARMACR (APNHY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (APNHY) Outperforming Other Medical Stocks This Year?
Should Value Investors Buy ASPEN PHARMACR (APNHY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing ASPEN PHARMACR (APNHY) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy ASPEN PHARMACR (APNHY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy ASPEN PHARMACR (APNHY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.